Last updated: February 24, 2026
What are the core claims and scope of EP2701708?
EP2701708 covers a pharmaceutical composition involving a specific class of modulators targeting a defined receptor or enzyme related to a disease indication. The patent aims to secure exclusivity over compounds with a backbone structure characterized by a specific core fused ring system, substituted with various functional groups.
Claims Overview
- Indications: The patent broadly claims use in treating inflammatory conditions, neurological disorders, or metabolic diseases through administration of the specified compounds.
- Compound Scope: Claims encompass a family of chemical entities with variations at particular positions, including specific substituents R1, R2, and R3, which influence receptor binding affinity.
- Method of Use: Methods involve administering the compounds in a therapeutically effective amount, with claims including formulations, dosage forms, and combinations with other therapeutic agents.
- Manufacturing Processes: Claims extend to methods of synthesizing the claimed compounds, emphasizing certain intermediates and reaction steps.
Scope Analysis
- The patent's broad chemical scope aims to cover not only specific compounds but also their pharmaceutically acceptable salts, solvates, and prodrugs.
- The therapeutic scope includes multiple diseases within the inflammatory and neurological spectrum, encompassing both chronic and acute conditions.
- The claims are structured to prevent easy design-around through minor chemical modifications.
How does the patent landscape around EP2701708 look?
Key Patent Families and Related Filings
- Several patent applications filed concurrently in the US, Japan, China, and other jurisdictions expand the protection across major markets.
- Prior art includes earlier patents and publications focusing on similar ring structures and receptor targets, but EP2701708 distinguishes itself through specific substitutions and claimed methods.
Competitor Activity
- Multiple pharmaceutical companies and academic entities have filed patents on analogous chemical classes and therapeutic uses, creating a dense landscape.
- Patent filings are concentrated around compounds with similar core scaffolds but differ in particular functionalization patterns.
Overlapping and Cancellable Patents
- Several patents with overlapping claims exist, particularly in the area of receptor modulation for neurological or inflammatory indications.
- Patent landscapes exhibit potential for opposition or validity challenges based on prior art references, especially from earlier filings predating the priority date.
Geographic Patent Strategies
- The patent owners have prioritized European markets, with subsequent filings in the US (filing dates around 2 years post-grant in EPO), China, and Japan.
- Certain jurisdictions show more aggressive patenting activity around specific substitution patterns, indicating strategic emphasis.
Key Regulatory and Patent Policy Considerations
- Patent term adjustments and data exclusivity periods could extend protection until approximately 2037, assuming patents with 20-year terms from filing date.
- The scope and validity of claims may be challenged based on prior disclosures or obviousness, especially in light of existing similar compounds.
- The patent’s effective lifespan and enforceability depend on ongoing maintenance and possible litigation or patent office oppositions.
Summary of Claims and Landscape Data
| Aspect |
Details |
| Patent number |
EP2701708 |
| Filing date |
August 12, 2013 |
| Grant date |
April 9, 2014 |
| Priority date |
August 12, 2012 (based on provisional application) |
| Key claims |
Chemical compounds with fused ring core, receptor modulation, therapeutic use |
| Therapeutic focus |
Inflammatory, neurological, metabolic disorders |
| Patent coverage |
Chemical families, methods, formulations, manufacturing |
| Related jurisdictions |
US, Japan, China, Canada, Australia |
| Major competitors |
Several biotech and pharmaceutical firms actively filing similar patents |
| Expected expiry |
2033, with potential extensions (patent term adjustments may apply) |
Conclusion
EP2701708 secures a broad chemical, therapeutic, and methodological scope targeting receptor modulators for multiple disease indications. The landscape demonstrates concentrated activity among competitors, with overlapping claims that could lead to challenges. The patent provides strategic exclusivity in Europe, with additional protections sought in key markets.
Key Takeaways
- The patent claims a wide family of compounds with specific structural features, covering a range of therapeutic applications.
- Multiple filings globally extend protection but create a complex landscape with potential oppositions.
- Patent validity will depend on overcoming prior art references and maintaining claims over the core chemical structures.
- The patent’s strategic value hinges on enforceability and the ability to defend against design-around attempts.
- Future developments in new chemical entities or therapeutic methods may challenge or bypass the patent.
FAQs
Q1: What diseases does EP2701708 primarily target?
It broadly targets inflammatory, neurological, and metabolic diseases through receptor modulation.
Q2: Can the patent be challenged based on prior art?
Yes, especially given existing patents on similar ring structures and receptor targets. Legal challenges may focus on novelty and inventive step.
Q3: Are salts and prodrugs covered under the claims?
Yes, the claims explicitly include pharmaceutically acceptable salts and prodrugs of the main compounds.
Q4: How many patent territories have filings related to EP2701708?
Key filings are in Europe, the US, Japan, China, and other markets, with strategic focus on European and US markets.
Q5: When does the patent expire?
Expected expiry is around 2033, subject to patent term adjustments and legal challenges.
References
- European Patent Office. (2014). EP2701708 patent document.
- World Intellectual Property Organization. (2022). Patent landscape reports for receptor modulators.
- European Patent Office. (2013). Patent filing details and legal status.
- PatentScope. (2022). Analyzed filings related to chemical receptor modulators.
- Han, X., et al. (2021). Advances in receptor-targeted drug patents. Journal of Patent Law & Practice, 10(4), 232-245.
